Elad Gil and IVP led a $250m Series D round in Abridge.

Elad Gil, an entrepreneur, operating executive, and investor or advisor to private companies, and IVP, a venture capital firm focused on fast-growing technology companies, led a $250m Series D round in Abridge, a generative AI platform for clinical conversations, with participation from Bessemer Venture Partners, California Health Care Foundation, CapitalG, CVS Health Ventures, K. Ventures, Lightspeed Venture Partners, NVentures, Redpoint Ventures, Spark Capital, and SV Angel. “Our health system is remarkable for its scientific and clinical achievements, but also overwhelmed and demoralized by bureaucratic processes, unproductive steps, and tedious labor. AI can be transformative by abstracting away the complexity and rules around revenue cycle as it pertains to documentation, allowing clinicians to focus on their patients while getting their documentation right the first time. Abridge is pioneering this effort with leading health systems across the country,” Somesh Dash, IVP General Partner.